Target Ovarian Cancer's research policies
Use of animals in medical research
Target Ovarian Cancer would like to see future advances made without research involving animals, but currently work with animals continues to be essential in some aspects of medical research. Target Ovarian Cancer therefore supports such work where no alternative exists and where it is carried out according to best practice as laid down in legislation.
Research using animals has made an important contribution to advances in medicine and surgery, which have brought major improvements in the health of human beings and animals.
Much basic research on physiological, pathological and therapeutic processes still requires the use of animals in experiments. Such research has provided and continues to provide the essential foundation for improvements in medical and veterinary knowledge, education and practice.
Research using animals will continue to be essential for the conquest of many unsolved medical problems, such as cancer, cardiovascular disease, stroke, other infectious diseases and AIDS; and genetic, developmental, neurological and psychiatric conditions.
Target Ovarian Cancer will support research using animals in the UK only if:
• it is fully compliant with current Home Office legislation
• it has been approved by a local ethics committee
• animal welfare is ensured
• it has been successfully independently peer reviewed and
• due consideration has been given to the refinement, reduction or replacement of the animals in the experiment and no viable non-animal alternatives exist (see http://www.nc3rs.org.uk/)
Target Ovarian Cancer believes that a dialogue on the use of animals in research is healthy and should be supported, and that the research community should explain the methods and aims of its research.
Position statement in support of open and unrestricted access to published research
The mission of Target Ovarian Cancer is to support the brightest minds in cancer research.
The main output of this research is new ideas and knowledge, which Target Ovarian Cancer expects its researchers to publish in high-quality, peer-reviewed journals.
Target Ovarian Cancer believes that maximising the distribution of these papers - by providing free, online access - is the most effective way of ensuring that the research we fund can be accessed, read and built upon. In turn, this will foster a richer research culture.
Target Ovarian Cancer therefore supports unrestricted access to the published output of research as a fundamental part of its charitable mission and a public benefit to be encouraged wherever possible.
It is a condition of funding that all original papers published from research that is wholly or substantially funded by Target Ovarian Cancer are deposited in the open access repositories PubMedCentral (PMC) and PMC’s linked sister repository in the UK, UKPubMedCentral (UKPMC) within six months of publication. This policy does not extend to reviews, book chapters, editorials or conference proceedings.